Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Receivables (2016 - 2025)

Cross Country Healthcare's Receivables history spans 16 years, with the latest figure at $172.4 million for Q4 2025.

  • For Q4 2025, Receivables fell 25.86% year-over-year to $172.4 million; the TTM value through Dec 2025 reached $172.4 million, down 25.86%, while the annual FY2025 figure was $172.4 million, 25.86% down from the prior year.
  • Receivables reached $172.4 million in Q4 2025 per CCRN's latest filing, down from $185.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $927.1 million in Q1 2022 to a low of $172.4 million in Q4 2025.
  • Average Receivables over 5 years is $450.1 million, with a median of $365.3 million recorded in 2023.
  • Peak YoY movement for Receivables: soared 270.5% in 2022, then plummeted 49.7% in 2024.
  • A 5-year view of Receivables shows it stood at $633.9 million in 2021, then increased by 2.39% to $649.0 million in 2022, then dropped by 28.78% to $462.3 million in 2023, then tumbled by 49.7% to $232.5 million in 2024, then dropped by 25.86% to $172.4 million in 2025.
  • Per Business Quant, the three most recent readings for CCRN's Receivables are $172.4 million (Q4 2025), $185.8 million (Q3 2025), and $213.1 million (Q2 2025).